Institute of Virology, Department of Hygiene, Microbiology and Public Health, Medical University of Innsbruck, Peter-Mayr-Str. 4b, Innsbruck 6020, Austria.
Department of Medical Statistics, Informatics and Health Economics, Medical University of Innsbruck, Austria.
EBioMedicine. 2021 Aug;70:103534. doi: 10.1016/j.ebiom.2021.103534. Epub 2021 Aug 12.
Background In early March 2020, a SARS-CoV-2 outbreak in the ski resort Ischgl in Austria triggered the spread of SARS-CoV-2 throughout Austria and Northern Europe. In a previous study, we found that the seroprevalence in the adult population of Ischgl had reached 45% by the end of April, representing an exceptionally high level of local seropositivity in Europe. We performed a follow-up study in Ischgl, which is the first to show persistence of immunity and protection against SARS-CoV-2 and some of its variants at a community level. Methods Of the 1259 adults that participated in the baseline study, 801 have been included in the follow-up in November 2020. The study involved the analysis of binding and neutralizing antibodies and T cell responses. In addition, the incidence of SARS-CoV-2 and its variants in Ischgl was compared to the incidence in similar municipalities in Tyrol until April 2021. Findings For the 801 individuals that participated in both studies, the seroprevalence declined from 51.4% (95% confidence interval (CI) 47.9-54.9) to 45.4% (95% CI 42.0-49.0). Median antibody concentrations dropped considerably (5.345, 95% CI 4.833 - 6.123 to 2.298, 95% CI 2.141 - 2.527) but antibody avidity increased (17.02, 95% CI 16.49 - 17.94 to 42.46, 95% CI 41.06 - 46.26). Only one person had lost detectable antibodies and T cell responses. In parallel to this persistent immunity, we observed that Ischgl was relatively spared, compared to similar municipalities, from the prominent second COVID-19 wave that hit Austria in November 2020. In addition, we used sequencing data to show that the local immunity acquired from wild-type infections also helped to curb infections from variants of SARS-CoV-2 which spread in Austria since January 2021. Interpretation The relatively high level of seroprevalence (40-45%) in Ischgl persisted and might have been associated with the observed protection of Ischgl residents against virus infection during the second COVID-19 wave as well as against variant spread in 2021. Funding Funding was provided by the government of Tyrol and the FWF Austrian Science Fund.
2020 年 3 月初,奥地利伊施格尔的 SARS-CoV-2 爆发引发了 SARS-CoV-2 在奥地利和北欧的传播。在之前的一项研究中,我们发现到 4 月底,伊施格尔的成年人口的血清阳性率已达到 45%,这代表了欧洲当地血清阳性率异常高的水平。我们在伊施格尔进行了一项随访研究,这是首次在社区层面显示出对 SARS-CoV-2 及其一些变体的免疫持久性和保护作用。
在参加基线研究的 1259 名成年人中,有 801 名被纳入 2020 年 11 月的随访研究。该研究涉及结合抗体和中和抗体以及 T 细胞反应的分析。此外,还比较了伊施格尔的 SARS-CoV-2 及其变体的发病率与 2021 年 4 月前蒂罗尔类似市的发病率。
对于参加两项研究的 801 名个体,血清阳性率从 51.4%(95%置信区间(CI)47.9-54.9)下降至 45.4%(95%CI 42.0-49.0)。抗体浓度明显下降(5.345,95%CI 4.833-6.123 至 2.298,95%CI 2.141-2.527),但抗体亲和力增加(17.02,95%CI 16.49-17.94 至 42.46,95%CI 41.06-46.26)。只有一个人失去了可检测到的抗体和 T 细胞反应。与类似的市镇相比,随着 2020 年 11 月奥地利第二波 COVID-19 的到来,伊施格尔相对幸免,与此同时,我们观察到这种持续的免疫也起到了一定作用。此外,我们还利用测序数据表明,从野生型感染中获得的当地免疫力也有助于抑制自 2021 年 1 月以来在奥地利传播的 SARS-CoV-2 变体的感染。
伊施格尔相对较高的血清阳性率(40-45%)持续存在,这可能与观察到的伊施格尔居民在第二波 COVID-19 期间免受病毒感染以及免受 2021 年变体传播的保护有关。
资金由蒂罗尔州政府和奥地利科学基金会提供。